R&D and Manufacturing

研发与制造

R&D Overview

Poly Pharm adheres to the advanced manufacturing positioning of "differentiation + vertical integration of API and finished product  + internationalization", strictly requiring drug quality comply with international GMP  standards. It has established a complete quality system, standardized quality management and control systems, procedures and standards. The company has accumulated rich technical reserves and experience in drug formulation technology research and formulation global registration. In recent years, the company has continuously increased its R&D investment in the combination of"generic and innovative" research, targeting at those products with high technical difficulty and differentiation, and it has established an innovative drug research institute, a biotechnology research institute, a generic drug research institute, and a API research institute, with over 550 R&D personnel, accounting for one-third of the company's total employees.


R&D achievements

The company has obtained over 97 patents, including 80 invention patents, and has been granted 260 product approvals, including 82 for domestic chemical drugs, 121 for overseas preparation production permits in Europe and America, 44 for active pharmaceutical ingredient production permits and filings, and 8 for pharmaceutical excipient production permits and filings. Currently, there are over 150 ongoing research and development projects, involving first-to-file + patent challenge generic drugs, improved 505b(2) new drugs, and new entity compound drugs.

  • 97

    + item

    Invention patents

  • 260

    pcs

    Product approval

  • 82

    + item

    Domestic chemical drug approvals

  • 121

    pcs

    Production permits for preparations to overseas markets

  • 44

    pcs

    API production approvals

features

XML 地图 | Sitemap 地图
友情链接:皇冠crown  皇冠crown  亚盈app  PG电子  bbin糖果派对试玩网站  pt游戏网站  银河官网入口  千亿体育  bbin游戏官网  九州bet